Why are both Foundayo and Zepbound made by Eli Lilly?

Both are Lilly products with different molecules and administration: Foundayo is daily oral orforglipron; Zepbound is weekly injected tirzepatide. Corporate strategy is not evidence that either is clinically superior or intended for a fixed patient segment.

Is Zepbound more effective than Foundayo?

Separate trials show substantial average loss with each, but do not establish a causal eight-to-ten-point advantage. SURMOUNT-1 and ATTAIN-1 differ in regimen and estimand; SURMOUNT-5 compared tirzepatide with semaglutide, not Foundayo.

Why would anyone choose Foundayo over Zepbound?

An eligible adult may prefer a daily non-fasting tablet or avoiding injections. Actual risks, interaction profile, adherence, response and net cost matter; neither a target percentage nor an old list price determines suitability.

How do the side effects compare?

Both can cause GI symptoms, but the assessed evidence does not prove equal rates or a daily-versus-weekly nausea pattern. Foundayo has product-specific interaction precautions and a thyroid boxed warning despite not producing rodent C-cell tumors in its own studies.

Can I switch from Zepbound to Foundayo?

A clinician can assess a change, but there is no validated universal milligram conversion or guarantee of weight maintenance. Do not start Foundayo at historical trial 6 or 12 mg because Zepbound was tolerated; use the marketed product label and individualized prescription.

Which is better for type 2 diabetes?

Mounjaro is the tirzepatide diabetes brand with a current label that includes glycemic control and specified adult cardiovascular-risk reduction. Foundayo’s assessed label is for adult weight management; trial diabetes findings do not establish a future approval date.

What about cardiovascular and other outcomes?

Mounjaro’s current CV indication, Zepbound’s OSA indication, and SUMMIT HFpEF evidence are distinct contexts. Foundayo predicted-risk analyses do not replace an event-outcome trial. Wegovy also has a specified CV indication supported by SELECT.

Will Foundayo make Zepbound cheaper?

Future pricing cannot be predicted from market strategy. Check current product-, presentation-, dose- and eligibility-specific manufacturer terms and the pharmacy or plan quote. No universal annual saving or price-convergence forecast is established.

Foundayo vs Zepbound: Oral Pill vs Dual-Agonist Injection

By the Peptide Dossier Editorial TeamUpdated October 27, 2026How we source

Compare approved Foundayo tablets and Zepbound injections using product-specific labels, separate weight trials, safety considerations and current access questions.

Quick Comparison Table

Foundayo and Zepbound distinctions
Question	Product or finding	Clinical limit
Mechanism	Orforglipron: GLP-1; tirzepatide: GIP/GLP-1	No fixed mechanism-derived loss ratio
Administration	Daily tablet versus weekly subcutaneous injection	Different adherence and handling needs
Maximum	Foundayo 17.2 mg daily; Zepbound 15 mg weekly	No milligram conversion
Evidence	Positive separate placebo-controlled studies	No head-to-head superiority conclusion

Mechanism: GLP-1 Solo vs GIP Plus GLP-1

Foundayo’s current label identifies orforglipron as an approved oral, nonpeptide small-molecule GLP-1 agonist for adult weight management at its obesity/overweight-with-comorbidity criteria. Its April 2026 approval is established; it is not merely awaiting an obesity submission. Tirzepatide activates GIP and GLP-1 receptors, whereas semaglutide and orforglipron activate GLP-1 receptors. A receptor count does not quantify an individual response.

The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.

Efficacy: Positive Results Without a Direct Comparison

ATTAIN-1 randomized 3,127 adults with obesity or overweight plus a complication, without diabetes, to daily orforglipron or placebo for 72 weeks alongside lifestyle care. Published treatment-regimen mean changes were −7.5%, −8.4% and −11.2% at historical investigational 6/12/36 mg versus −2.1% with placebo. The sponsor’s 12.4% highest-dose figure uses an efficacy estimand assuming treatment as intended. Both are positive findings; neither is a direct comparison with Wegovy or tirzepatide. The trial was Lilly-funded, and the marketed formulation has different strength numbers.

STEP 1 tested weekly semaglutide 2.4 mg in 1,961 adults without diabetes: mean treatment-policy loss was 14.9% versus 2.4% with placebo at 68 weeks. SURMOUNT-1 tested tirzepatide in 2,539 adults without diabetes: treatment-regimen losses at 72 weeks were 15.0%, 19.5% and 20.9% at 5/10/15 mg versus 3.1% with placebo. These separate trials do not establish a head-to-head difference; the frequently quoted 22.5% uses a different estimand.

SURMOUNT-5 directly compared tirzepatide against injected semaglutide, not Foundayo. Separate mean losses do not establish an 8–10-point causal advantage, equivalent success at a chosen target, or predictable pounds lost.

Cost: Compare the Actual Product and Program

Compare the current exact prescription and program terms. A manufacturer list price, pharmacy retail quote, self-pay offer and insured copay are different figures; introductory dose offers are not maintenance prices. Neither a $499 Foundayo example nor a $1,349 Wegovy or $1,086 Zepbound historical list-price example establishes today’s personal cost or an annual saving. The CMS GLP-1 Bridge is a separate, conditional pathway for qualifying beneficiaries and products; it does not mean all Medicare patients receive either medicine for $50. Check plan, indication, formulation and eligibility.

Convenience: Daily Tablet and Injection Trade-offs

Foundayo is taken whole once daily with or without food; do not split, crush or chew tablets or take more than one in a day. Oral dosing avoids injections, but daily adherence, travel temperature limits and interactions still matter. The label includes specific CYP3A4/OATP-related interaction instructions and a simvastatin limit; “no fasting requirement” does not mean no medication restrictions. Use the actual label.

Zepbound’s devices have product-specific injection, storage and room-temperature instructions. Needle avoidance is useful, but no-refrigeration preference does not make one oral product the only viable treatment for every traveler or person without stable housing.

Related reading: Zepbound injection sites.

Side Effects: Both GI-Heavy, Different Patterns

Both products can cause GI symptoms and have important product-specific warnings. Foundayo carries a boxed thyroid C-cell tumor warning and contraindications for personal/family MTC, MEN2 or serious hypersensitivity. Unlike semaglutide/tirzepatide rodent findings, orforglipron was not active at rodent GLP-1 receptors and did not cause rat/mouse C-cell tumors; its label describes uncertainty about relevance of the class finding to humans. Do not claim confirmed human thyroid cancer, zero risk, or equal safety rates from unmatched trials. Read the label for severe GI events, pancreatitis, gallbladder disease, dehydration-related kidney injury, interactions, pregnancy and anesthesia precautions.

Nausea, diarrhea, vomiting, constipation and abdominal symptoms occur with both treatments, commonly during escalation. Separate label pools differ in dose, population and follow-up, so a table of unmatched percentages cannot rank tolerability. SURMOUNT-5 reported mainly mild-to-moderate GI events during escalation; it was not designed to establish a definitive safety winner. Symptoms may improve, persist or require dose changes or stopping.

Cardiovascular and Other Outcomes

Established cardiovascular outcome evidence is product- and population-specific. SELECT tested injected semaglutide 2.4 mg in 17,604 adults with established cardiovascular disease and overweight/obesity without diabetes: MACE occurred in 6.5% versus 8.0% with placebo over mean 39.8 months (hazard ratio 0.80). Wegovy’s current label includes a specified CV indication, including its tablet formulation under the label. A predicted-risk score analysis of Foundayo is not a completed cardiovascular-event trial or proof of equivalent benefit.

Zepbound has an OSA indication in eligible adults with obesity. SUMMIT’s HFpEF evidence and Mounjaro’s diabetes CV indication are separate study/brand contexts, not automatic expansion of every tirzepatide label.

Who Should Choose Foundayo

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

Foundayo may suit an eligible adult who prefers a daily non-fasting tablet and can follow its interaction and safety requirements.

Who Should Choose Zepbound

Mounjaro starts at 2.5 mg once weekly; increases in 2.5-mg steps require additional glycemic control and at least four weeks at the current dose. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at the current dose, considering response and tolerability. Adult maximum is 15 mg; Mounjaro’s pediatric maximum is 10 mg. Zepbound weight-management maintenance doses are 5, 10 or 15 mg, whereas its OSA maintenance doses are 10 or 15 mg. A maximum is not a target for everyone.

The Lilly Strategy

Both products are made by Lilly, but corporate market strategy does not establish comparative safety, efficacy, cost or which medicine a patient should receive. Current oral Wegovy is also an approved alternative, so Foundayo is not the only needle-free GLP-1 weight treatment.

Bottom Line

A clinician may consider changing products after reviewing the last dose, interruption, adverse effects, other medicines and clinical goal. There is no universal dose equivalence or safe washout calendar between these drugs. Do not start Foundayo at historical trial 6/12/36 mg because a previous injection was tolerated, overlap GLP-1 medicines, or assume a pill reliably maintains every person’s prior weight loss.

Lilly’s May 2026 ATTAIN-MAINTAIN report describes 376 selected SURMOUNT-5 completers in a randomized, placebo-controlled 52-week maintenance study. Foundayo met the primary maintenance endpoint; efficacy-estimand mean regain after switching was 0.9 kg from prior Wegovy and 5.0 kg from prior Zepbound. The reported primary analysis in plateaued participants and these subgroup weight-change summaries are different measures. This favorable sponsor-reported evidence supports further maintenance options, not guaranteed maintenance after any oral or injected regimen. Its investigational starting dose is study methodology, not a replacement for current labeled initiation.

No individual efficacy or cost result is guaranteed. Use current product-specific prescribing and program information.